Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) | MicrobiomeTrials← Back to trialsNCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-07-30Est. Completion: 2028-01-01
Enrollment target: 15 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Multicausal FatigueFatiguePost COVID ConditionLong COVID SyndromePostviral Fatigue
This proof-of-concept study aims to evaluate the feasibility, acceptability, and potential benefits of a novel multimoda…
Basel, SwitzerlandEst. completion Aug 2027
Post-Acute COVID-19 SyndromeLong COVIDBrain Fog
The pandemic has highlighted social, economic, educational, and political issues that have affected the health and quali…
Macaíba, BrazilCompleted May 30, 2026